Skip to main content
. 2016 Jul 7;22(25):5678–5693. doi: 10.3748/wjg.v22.i25.5678

Table 1.

Associated biomarkers for colorectal cancer and their predictive value

Biomarkers
Molecular basis Predictive value Detection method
Category Type
Pathological characteristics Tumor stage Diagnostic, prognostic and predictive markers Diagnostic radiology and pathological/cytological examination
Lymph node status
Grade of differentiation
Anatomy of invasion
Proliferation markers Ki67 Nuclear antigen associated with proliferation Diagnostic and prognostic markers IHC
Cyclins Regulation of cell cycle phase transition Diagnostic and prognostic markers IHC
Chromosome abnormalities p53 Tumor suppressor gene which shows loss of function Diagnostic, prognostic and predictive markers IHC, RT-PCR, FISH
H-ras, K-ras, N-ras Membrane-associated GTPase integral to signal transduction cascade, if mutated, causes increased cellular proliferation Diagnostic, prognostic and predictive markers IHC, RT-PCR, FISH
Telomere length Pathologic telomere length dynamics Diagnostic and prognostic markers RT-PCR, Flow cytometry
Telomerase activity Maintenance of telomeres and therefore chromosomal length Diagnostic and prognostic markers TRAP assay
enables progression through successive cell cycles
Hypoxia-regulated genes HIF-1 HIF-1 transcription factor complex stabilized in hypoxic conditions, leading to transcription of hypoxia-regulated genes Diagnostic and prognostic markers IHC
Glut-1 Increased Glut-1 expression caused by malignant transformation and upregulated by hypoxia. Promotes switch to anaerobic glycolysis to support hypoxic tumor Diagnostic and prognostic markers IHC
Angiogenesis VEGF Angiogenic growth factor Prognostic and predictive markers IHC, FISH, immunoassay
PD-ECGF Angiogenic growth factor with thymidine phosphorylase activity Prognostic and predictive markers IHC
Vascularity New vasculature supports tumor growth Prognostic and predictive markers IHC staining for endothelial receptors e.g., CD31, CD34, von Willebrand (factor VIII) combined with measurement of ICD or MVD using digital image analysis techniques
Epigenetics Aberrant DNA hypermethylation Inactivation of key tumor suppressor genes including APC, ATM, BMP3, CDKN2A, SFRP2, GATA4, GSTP1, HLTF, MLH1, MGMT, NDRG4, RASSF2A, SFRP2, TFPI2, VIM, and WIF1 Diagnostic, prognostic and predictive markers PCR-based methods and Pyrosequencing
Aberrant DNA hypomethylation Lids to chromosomal instability and global loss of imprinting Diagnostic and prognostic markers PCR based methods and Pyrosequencing
Tumor specific expression patterns Gene expression patterns Unique signature of the dysregulated genes/pathways at different forms and stages of CRC Diagnostic, prognostic and predictive markers Array-based methods, NGS, RT-PCR
MicroRNA expression patterns Unique signature of the dysregulated microRNAs at different forms and stages of CRC Diagnostic, prognostic and predictive markers Array-based methods, NGS, RT-PCR

FISH: Fluorescent in-situ hybridization; HIF-1: Hypoxia inducible factor-1; HPLC: High pressure liquid chromatography; ICD: Intercapillary distance; IGF-1: Insulin growth factor-1; IHC: Immunohistochemistry; MVD: Microvessel density; NGS: Next generation sequencing; PD-ECGF: Plateletderived endothelial cell growth factor; RT-PCR: Reverse transcription–polymerase chain reaction; RIA: Radioimmunoassay; VEGF: Vascular endothelial growth factor.